COVID-19 Drug Remdesivir Shows 'Clear-cut Positive Effect' in U.S. Trial
The experimental antiviral holds promise as a treatment
Remdesivir, an experimental antiviral drug produced by biotech firm Gilead Sciences, has been one of the most talked about treatment options said preliminary data from a US-based clinical trial showed it can help patients ., even in the face of conflicting reports about its potential. On Wednesday, the US National Institute of Allergy and Infectious Diseases (NIAID)
The preliminary findings were shared by Dr. Anthony Fauci, the director of the NIAID, during a press briefing at the White House on Wednesday. Fauci said the early results are "a very important proof-of-concept because what it has proven is that a drug can block this virus." However, the full peer-reviewed data from the trial are yet to be released but will be available in a forthcoming report, according to NIAID.
Remdesivir isn't specifically designed to destroy SARS-CoV-2, the virus that causes COVID-19. Instead, it knocks out a specific piece of machinery viruses use to replicate, known as "RNA polymerase." It was originally designed as a drug to treat Ebola, but when trialed, it turned out to be mostly unsuccessful. In 2017, a study published in the journal Science showed remdesivir to be effective against human coronaviruses in cells and mouse models.
Please select this link to read the complete article from C|NET.